BioVaxys Technology Corp. Launches LIFE Offering to Enhance Research and Development Efforts

BioVaxys Technology Corp. Announces LIFE Offering

BioVaxys Technology Corp. from Vancouver, BC, is making waves in the biopharmaceutical sector with its latest announcement regarding a non-brokered private placement offering. The company plans to offer a minimum of 7,058,824 units priced at $0.17 each, raising a total of $1,200,000, with a maximum possible offering of 9,411,764 units to reach up to $1,600,000 in gross proceeds.

Details of the Offering

Each unit will consist of one common share and one purchase warrant, permitting investors to acquire additional shares at a price of $0.40 within 24 months of issuance. The offering aims to close by a date determined by the company, but it must occur within 45 days of the announcement, dependent on regulatory approvals, including those from the Canadian Securities Exchange (CSE).

The proceeds generated from this life offering are earmarked for significant uses aimed at enhancing the company's research capabilities. Key initiatives include:

1. Pursuing Licensing Opportunities: BioVaxys intends to explore various licensing opportunities and research collaborations to utilize its innovative DPX solutions effectively. This focus positions the company as a valuable partner for targeted immunotherapy developments.

2. Advancing Research for Allergies: The company plans to identify sufficient graded supply for its DPX technologies, specifically aimed at formulating a peanut allergy vaccine. This research is critical as food allergies have become a significant public health concern.

3. Initiating Clinical Trials: The offering will also support the commencement of a clinical study at McMaster University for the preclinical proof of concept regarding a prophylaxis vaccine targeting peanut allergens.

4. Patent Development and Maintenance: BioVaxys will be filing new patents to broaden its intellectual property while maintaining existing patents through necessary annuity payments.

5. Completing Data Analysis for Immunological Studies: The final allocation of funds will be used to analyze immunological data from phase 1 studies, essential for licensing discussions in various tumor types.

Strategic Offering Approach

The Units will be available for sale through the Listed Issuer Financing Exemption under National Instrument 45-106. Notably, the securities sold through this exemption are exempt from the typical hold periods in Canadian securities laws, providing an attractive proposition for potential investors. Furthermore, the company may offer finder’s fees to individuals or entities that introduce investors to BioVaxys as part of this offering.

Prospective investors are encouraged to review the offering document, dated October 7, 2025, which is accessible through BioVaxys' profile on SEDAR+ or the company’s official website.

A Forward-Looking Perspective

This announcement indicates a deliberate stride by BioVaxys to enhance its innovative approach in the biopharmaceutical landscape. The company is keen on leveraging its DPX™ immune-educating technology platform and HapTenix© tumor cell construct for critical immunological diseases, including cancers and allergies.

Currently, BioVaxys holds a clinical-stage pipeline including MVP-S, designed for advanced cancer treatments, which has shown significant promise in improving patient outcomes. Through strategic financing such as this LIFE offering, the company seeks to expand its capabilities and responsiveness to the urgent healthcare needs of society.

BioVaxys shares are publicly traded on several markets, including the CSE as